A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

(MedPage Today) — An oral investigational agent, gildeuretinol (ALK-001), demonstrated a significant reduction in geographic atrophy (GA) lesion growth and improvements in low luminance visual function in the phase II SAGA trial, according to…

Source link : https://www.medpagetoday.com/meetingcoverage/arvovideopearls/115716

Author :

Publish date : 2025-05-22 15:58:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

AI Passes Gastro Board Exam; ALD Hospitalizations Surge; Post-Colonoscopy CRCs

Special contact lenses let you see infrared light – even in the dark

Related Posts

Reinstated NIOSH Workers Still Don’t Feel Secure

RFK Jr. Releases Much-Anticipated MAHA Report

The Trouble With ‘Do Your Own Research’ for Drugs

MDs React to Biden Dx; Watch Doc Pay Off Final Student Loan; Getting Real With MAHA

‘There’s No Conspiracy’: An Inside Look at CDC’s Key Vaccine Safety Database

Special contact lenses let you see infrared light – even in the dark

Reinstated NIOSH Workers Still Don’t Feel Secure

RFK Jr. Releases Much-Anticipated MAHA Report

The Trouble With ‘Do Your Own Research’ for Drugs

MDs React to Biden Dx; Watch Doc Pay Off Final Student Loan; Getting Real With MAHA

‘There’s No Conspiracy’: An Inside Look at CDC’s Key Vaccine Safety Database

Penguin poo helps keep Antarctica cool

Special contact lenses let you see infrared light – even in the dark

A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

Categories

Archives